According to the Zhitong Finance APP, GUANZE MEDICAL (02427) announced its mid-term performance for 2024, with revenue of 40.03 million yuan, a decrease of 46.2% compared to the same period last year; the attributable loss to owners of the parent company was 0.16 million yuan, compared to a profit of 15.948 million yuan in the same period last year; loss per share was 0.0002 yuan.

The announcement stated that the decrease in revenue was mainly due to a decrease in sales revenue of medical imaging film products. The sales revenue of medical imaging film products and software decreased by approximately 50.5% to approximately 33.6 million yuan during the period. This was primarily because the company's own brand, 'GUANZE Smart Medicine,' had a more affordable price compared to international brands provided by the company, which gained more customer recognition, resulting in an increase in the percentage of revenue contributed by the own brand to the total revenue of medical imaging film products from 50.3% in the same period last year to 93.8% during the period. The price of medical imaging film products decreased for some customers, and the unexpected decrease in customer demand due to economic downturn.